Ann Pharm Fr. 2024 Feb 8:S0003-4509(24)00006-3. doi: 10.1016/j.pharma.2024.02.001. Online ahead of print.


BACKGROUND: The expenses of multiple myeloma (MM) represent a real economic and societal burden for patients and health authorities. However, very little is known about the situation in Algeria. Therefore, the aim of this study is to evaluate the costs generated by the management of MM and its complications in Algerian patients.

MATERIALS AND METHODS: an observational retrospective study conducted on patients diagnosed with MM, from January 01st, 2019 to April 31st, 2023. At the Establishment Hospitalier Universitaire November 1st, Oran. A bottom-up costing methodology was used to assess the phase-specific cost and the complication burden.

RESULTS: 249 qualified for the study. For autologous stem cell transplantation (ASCT) eligible patients, the mean per-patient cost of treating myeloma was estimated at: induction regimen ($4 071,98); ASCT ($2 899,25); consolidation ($1 538,18); and maintenance ($355,76). The mean drug cost for ASCT-ineligible patients was $1 421,52. The use of generic bortezomib and generic melphalan has led to a reduction in expenses of $1 075 181,25 ($5 024,21 per patient; 55,35%) and $10 864,24 ($487,10 per patient; 15,07%), respectively. Another cost-saving adaptation was ASCT using non-cryopreserved (NC) stem cells. The cost of managing MM complications was $177 781,98 per year.

CONCLUSION: A number of adjustments have been implemented to the management of MM over time to improve clinical efficacy and reduce costs in Algeria. However, this may have come with a startlingly high cost of complications.

PMID:38340806 | DOI:10.1016/j.pharma.2024.02.001